RT Journal Article
SR Electronic
T1 De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational Study
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3713
OP 3718
DO 10.21873/invivo.12219
VO 34
IS 6
A1 SHOGO NAKAMOTO
A1 MASAHIKO IKEDA
A1 SHINICHIRO KUBO
A1 MARI YAMAMOTO
A1 TETSUMASA YAMASHITA
YR 2020
UL http://iv.iiarjournals.org/content/34/6/3713.abstract
AB Background: It is unclear whether the de-escalated therapy that omits anthracycline-based chemotherapy is as beneficial as standard therapy for patients with stage I human epidermal growth factor receptor 2-positive (HER2+) early breast cancer. Patients and Methods: We retrospectively investigated 95 patients with pathological stage I HER2+ early breast cancer who underwent adjuvant treatment from April 2009 to December 2018. Results: We assessed 45 patients who underwent standard therapy containing anthracyclines, 35 patients who underwent paclitaxel plus trastuzumab (P+TRA group), and 15 patients who underwent trastuzumab monotherapy or no adjuvant therapy; the 5-year invasive disease-free survival rates were 97.8%, 92.9%, and 93.3%, respectively (p=0.255). Adverse events were significantly less frequent in the P+TRA group than that in the standard therapy group. Conclusion: In a real-world setting, de-escalated therapy without anthracyclines demonstrated excellent outcomes similar to the standard therapy containing anthracyclines as well as lower adverse events.